GSK & Sanofi join forces to discover an effective vaccine for COVID-19
Category: #health  By Nikita Chaurasia  Date: 2020-04-15
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

GSK & Sanofi join forces to discover an effective vaccine for COVID-19

Amidst growing concerns over the coronavirus, numerous medical institutes and pharmaceutical companies are diligently working on developing an effective vaccine to tackle this deadly virus. France’s Sanofi S.A. and Britain’s GlaxoSmithKline plc (GSK) are a shining example of this statement as two of the world’s largest vaccine creators join forces to develop and mass produce a vaccine for COVID-19.

Reportedly, the pharma giants are planning to commence vaccine trials by the second half of 2020 and, if everything goes as per the plan, will make them widely accessible by Q2 of 2021.

According to Paul Hudson, Chief Executive Officer, Sanofi, during these unprecedented times where the whole world is going through a health crisis, a single company wouldn’t be able to tackle this issue. As a result, Sanofi believes it is beneficial for it to share its resources and expertise with its partners and allies like GSK. The main focus of this partnership is to create and provide ample quantities of drugs that would help cure this disease.

Currently, the market is crowded with dozens of teams ranging from universities to firms such as Moderna, Inovio and Johnson & Johnson who are constantly working on drug development and clinical trials. Most of them are on the verge of developing a sure shot vaccine for COVID-19, with almost 78 candidates being actively tested.

However, Sanofi and GSK believe that their size would give them a decisive edge over competitors, as the infected patients figure scales up to almost 2 million worldwide.

Speaking on the development, David Loew, Executive Vice President of Vaccine Branch, Sanofi Pasteur, said that the real challenge is to not just discover a suitable vaccine candidate but also to produce it at a massive scale, scaling up to hundreds of millions of doses.

Source Credit: https://www.euronews.com/2020/04/14/coronavirus-vaccine-pharma-giants-gsk-and-sanofi-team-up-to-find-covid-19-solution

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

U.K.’s competition regulator might look into the music streaming space

U.K.’s competition regulator might look into the music streaming space

By Nikita Chaurasia

The Competition and Markets Authority of the U.K. has revealed plans to launch a probe targeting the country’s music streaming market to ascertain if it is sufficiently consumer-centric and competitive. The announcement came after a U.K. parli...

India’s vaccination drive slows down as dose gap holds back output

India’s vaccination drive slows down as dose gap holds back output

By Nikita Chaurasia

India’s vaccination efforts have reportedly slowed down despite stockpiling vaccines as authorities are maintaining a more than usual gap between two shots. This is a part of the strategy to boost vaccine coverage in the country. The domestic ...

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

By Nikita Chaurasia

The McPlant patty is developed in collaboration with Beyond Meat Inc. It will be prepared using vegetarian ingredients like peas, potatoes, and rice. McDonald’s will reportedly start offering its first vegetarian option in the U.S., the ne...